| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6131267 | Clinical Microbiology and Infection | 2009 | 9 Pages |
Abstract
In recent years, a marked increase in the incidence of infections caused by methicillin-resistant Staphylococcus aureus (MRSA) has occurred in many countries. This review addresses the effectiveness and limitations of drugs classically used for the treatment of MRSA, e.g. vancomycin, and also newer anti-MRSA antimicrobials, e.g. second-generation glycolipopeptides, tigecycline, and β-lactams.
Related Topics
Life Sciences
Immunology and Microbiology
Microbiology
Authors
E. Bouza,